Evidence map›Paper›PMID 38781491›Full record

ArticleJournal of natural products2024

Metabolomic Analysis and Antiviral Screening of a Marine Algae Library Yield Jobosic Acid (2,5-Dimethyltetradecanoic Acid) as a Selective Inhibitor of SARS-CoV-2.

Marie L Matos-Hernández, Robert Samples, Grayce Dyer, Victoria M Casimir Montán, Chris A Morales-Colón, Joseph M Salvino, Luis J Montaner, Joel A Cassel, Troy E Messick, Ian Tietjen and 1 more

Abstract read
In one paragraph

Article in Journal of natural products, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. MarinePharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Marine natural products.Natural product reports · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marie L Matos-HernándezDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico 00935, United States.ORCID 0000-0003-0332-0942
Robert SamplesCenter for Mass Spectrometry, Smith College, Northampton, Massachusetts 01063, United States.ORCID 0000-0003-1745-4052
Grayce DyerDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico 00935, United States.ORCID 0009-0007-8309-1487
Victoria M Casimir MontánDepartment of Chemistry, Natural Sciences College, University of Puerto Rico-Rio Piedras Campus, San Juan, Puerto Rico 00925, United States.ORCID 0000-0002-8244-4662
Chris A Morales-ColónDepartment of Chemistry, Natural Sciences College, University of Puerto Rico-Rio Piedras Campus, San Juan, Puerto Rico 00925, United States.ORCID 0000-0002-7308-8395
Joseph M SalvinoThe Wistar Institute, Philadelphia, Pennsylvania 19104, United States.ORCID 0000-0002-2184-5980
Luis J MontanerThe Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Joel A CasselThe Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Troy E MessickThe Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Ian TietjenThe Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Eduardo J E Caro-DiazDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico 00935, United States.ORCID 0000-0002-2049-6248

Funding

Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Emma Fernandez-Repollet · 2017 to 2026
$35.8M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
G-RISE at the University of Puerto Rico Medical Sciences CampusT32GM148406 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI BARRETO ESTRADA, JENNIFER LUZ, CADILLA, CARMEN LYDIA · 2023 to 2024
$2.8M
NIGMS NIH HHS R25 GM061838NIGMS NIH HHS T32 GM148406NIMHD NIH HHS U54 MD007600
6 · The paper itself

Abstract

Current small-molecule-based SARS-CoV-2 treatments have limited global accessibility and pose the risk of inducing viral resistance. Therefore, a marine algae and cyanobacteria extract library was screened for natural products that could inhibit two well-defined and validated COVID-19 drug targets, disruption of the spike protein/ACE-2 interaction and the main protease (M

Indexed as

Antiviral AgentsMetabolomicsSARS-CoV-2Coronavirus 3C ProteasesCOVID-19CyanobacteriaFatty AcidsHumansMolecular StructureStructure-Activity RelationshipAntiviral AgentsCoronavirus 3C ProteasesFatty Acids

Identifiers

PMID38781491
PMCPMC12401496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.